SCHEMBL7968596

SCHEMBL7968596

Cc1c(C=O)sc2cccc(-c3sc(Nc4ccccc4)nc3N)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.48
MEN1 O00255 8/20 0.48
KMT2A Q03164 8/20 0.48
LMNA P02545 5/20 0.48
PSMD14 O00487 1/20 0.48
NPC1 O15118 6/20 0.41
RAB9A P51151 6/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 3/20 0.41
TP53 P04637 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
CDK5 Q00535 3/20 0.41
CDK5R1 Q15078 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 1/20 0.41
CCNA2 P20248 5/20 0.40
CDK2 P24941 5/20 0.40
GSK3B P49841 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1248421 0.76 CCNA2 (0.49) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL1250757 0.76 MAPT (0.52) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL7756995 0.74 MAPT (0.68) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL1248135 0.72 MAPT (0.45) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL7111272 0.72 CDK5 (0.43) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL1249747 0.69 MAPT (0.46) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL7753473 0.68 CDK2 (0.45) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL1250520 0.68 MAPT (0.45) MAPTMEN1KMT2ALMNAPSMD14
SCHEMBL7758207 0.68 MEN1 (0.57) MAPTMEN1KMT2ALMNANPC1
SCHEMBL7757594 0.68 MAPT (0.45) MAPTMEN1KMT2ALMNAPSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010039275-A1 Use of 2,4-diaminothiazole derivatives NOVO NORDISK A/S (DK) 2001-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039275-A1 Use of 2,4-diaminothiazole derivatives GSK3A, GSK3B, GSKIP MAPT 13/4885MEN1 3396/4885KMT2A 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.